Xiaowei Chen

Xiaowei Chen

Auto-generated profile, based on publicly available information

Xiaowei Chen

Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
YSYanfeng Song
Yanfeng Song
YLYing Liu
Ying Liu
XCXiaowei Chen
Xiaowei Chen
Song Y, et al. Yonsei Med J. 2018 May;59(3):416-424. https://doi.org/10.3349/ymj.2018.59.3.416

14 November 2019 in Cell Transplantation
Verified
Journal Article
Open access
PDF file
RZRuiqing Zhou
Ruiqing Zhou
WMWenjian Mo
Wenjian Mo
SWShunqing Wang
Shunqing Wang
WZWei Zhou
Wei Zhou
XCXiaowei Chen
Xiaowei Chen
SPShiyi Pan
Shiyi Pan
Numerous lines of evidence have shown that microRNAs (miRNAs) play a vital role in regulating the progression in many types of cancers, including T cell acute lymphoblastic leukemia (T-ALL). In this study, the potential underlying mechanism and functional role of miR-141-3p in T-ALL cells were determined. We found that the expression level of miR-141-3p was significantly downregulated, while that of tumor necrosis factor receptor-associated factor 5 (TRAF5) was strongly upregulated in tissues from patients with T-ALL compared with healthy controls. Subsequently, upregulation of miR-141-3p significantly repressed T-ALL cell proliferation and promoted cell apoptosis. Conversely, downregulation of miR-141-3p significantly inhibited cell apoptosis and enhanced T-ALL cell proliferation. We also verified that TRAF5 was the direct target of miR-141-3p in T-ALL cells. Additionally, TRAF5 overexpression significantly repressed cell apoptosis and increased T-ALL cell proliferation. In summary, miR-141-3p regulates T-ALL cell progression by directly targeting TRAF5, and may serve as a potential therapeutic target for T-ALL.